Type Mutant Stock; Transgenic; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Mating System Noncarrier x Hemizygote (Female x Male) 11-JUL-08 Species laboratory mouse Generation ?+N1F9 (01-JUL-11)
Generation DefinitionsDonating Investigator Virginia Lee, University of Pennsylvania Description
These transgenic mice express the P301S mutant human microtubule-associated protein tau, MAPT, under the direction of the mouse prion protein, Prnp, promoter. The expression of the mutant human MAPT is five-fold higher than the expression of the endogenous mouse MAPT protein. Hyperphosphorylated, insoluble mutant human MAPT protein in the brain accumulates with age causing decreased microtubule binding. At three months of age, transgenic mice exhibit clasping and limb retraction when lifted by the tail, which progresses to limb weakness. By 10 months of age the mice exhibit a hunched back and paralysis, followed by inability to feed. Transgenic mice have a median lifespan of approximately nine months with approximately 80% dying by 12 months. Histological analysis reveals neuron degeneration in hippocampus and ventricular dilatation (brain atrophy) by eight months of age, although significant neuron degeneration in the hippocampus occurs at approximately nine months of age. Neuron loss spreads to the amygdala, neocortex and entorhinal cortex by 12 months of age. Defective translocation of endoplasmic reticulum proteins in affected neurons is observed as early as three months of age. The onset of neurofibrillay tangle formation in the neocortex, amygdala, hippocampus, brain stem and spinal cord is five months of age. Transgenic mice display neuroinflammation with microglial activation and astrogliosis. The ultrastructure of the neurofibrillay tangle-like lesions detected is similar to that found in brain lesions of human Alzheimer's disease and tauopathy patients. Degradation of synaptic function is significant by six months of age. These mice cannot be bred to homozygosity, homozygous females do not mate. This mutant mouse strain may be useful in studies of neurodegenerative tauopathy and Alzheimer's disease.Development
A transgenic construct containing the P301S mutant human microtubule-associated protein tau, MAPT, under the direction of the mouse prion protein, Prnp, promoter was injected into fertilized B6C3F1 mouse eggs. Founder animals were bred to B6C3F1/J or B6C3F1/Crl mice. The resulting transgenic mice were maintained as hemizygotes on the B6C3F1 background before arriving at The Jackson Laboratory.
| Control | ||
|---|---|---|
| Noncarrier | ||
| 100010 B6C3F1/J | ||
| Considerations for Choosing Controls | ||
Alzheimer's Disease Models
005987 129-Achetm1Loc/J 006409 129S1.129(Cg)-Tg(APPSw)40Btla/Mmjax 008077 129S1/Sv-Bchetm1Loc/J 016198 129S6.Cg-Tg(Camk2a-tTA)1Mmay/JlwsJ 014556 129S6/SvEv-Apoetm4Mae/J 006555 A.129(B6)-Tg(APPSw)40Btla/Mmjax 005708 B6.129-Apbb1tm1Quhu/J 004714 B6.129-Bace1tm1Pcw/J 004098 B6.129-Klc1tm1Gsn/J 007251 B6.129-Mapttm1Hnd/J 004193 B6.129-Psen1tm1Mpm/J 003615 B6.129-Psen1tm1Shn/J 005300 B6.129-Tg(APPSw)40Btla/Mmjax 005617 B6.129P-Psen2tm1Bdes/J 002609 B6.129P2-Nos2tm1Lau/J 007685 B6.129P2-Psen1tm1Vln/J 007999 B6.129P2-Sorl1Gt(Ex255)Byg/J 008087 B6.129S1-Bchetm1Loc/J 002509 B6.129S2-Plautm1Mlg/J 005301 B6.129S2-Tg(APP)8.9Btla/J 004163 B6.129S4-Cdk5r1tm1Lht/J 010959 B6.129S4-Grk5tm1Rjl/J 010960 B6.129S4-Grk5tm2Rjl/J 002213 B6.129S4-Ngfrtm1Jae/J 006406 B6.129S4-Tg(APPSwLon)96Btla/Mmjax 006469 B6.129S4-Tg(PSEN1H163R)G9Btla/J 012564 B6.129S5-Dhcr24tm1Fein/SbpaJ 004142 B6.129S7-Aplp2tm1Dbo/J 004133 B6.129S7-Apptm1Dbo/J 013040 B6.Cg-Apoetm1Unc Ins2Akita/J 005642 B6.Cg-Clutm1Jakh/J 005491 B6.Cg-Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J 009126 B6.Cg-Nos2tm1Lau Tg(Thy1-APPSwDutIowa)BWevn/Mmjax 005866 B6.Cg-Tg(APP695)3Dbo Tg(PSEN1dE9)S9Dbo/Mmjax 008730 B6.Cg-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax 005864 B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax 007575 B6.Cg-Tg(CAG-Ngb,-EGFP)1Dgrn/J 016197 B6.Cg-Tg(CAG-OTC/CAT)4033Prab/J 005855 B6.Cg-Tg(Camk2a-Prkaca)426Tabe/J 007004 B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ 004996 B6.Cg-Tg(DBH-Gal)1923Stei/J 007673 B6.Cg-Tg(Gad1-EGFP)3Gfng/J 004662 B6.Cg-Tg(PDGFB-APP)5Lms/J 006293 B6.Cg-Tg(PDGFB-APPSwInd)20Lms/2Mmjax 006006 B6.Cg-Tg(Prnp-APP)A-2Dbo/J 008596 B6.Cg-Tg(Prnp-Abca1)EHol/J 006005 B6.Cg-Tg(Prnp-App/APPswe)E1-2Dbo/Mmjax 007180 B6.Cg-Tg(Prnp-ITM2B/APP695*40)1Emcg/J 007182 B6.Cg-Tg(Prnp-ITM2B/APP695*42)A12Emcg/J 005999 B6.Cg-Tg(SBE/TK-luc)7Twc/J 012597 B6.Cg-Tg(Thy1-COL25A1)861Yfu/J 007051 B6.Cg-Tg(tetO-APPSwInd)102Dbo/Mmjax 007052 B6.Cg-Tg(tetO-APPSwInd)107Dbo/Mmjax 007049 B6.Cg-Tg(tetO-APPSwInd)885Dbo/Mmjax 009337 B6.FVB-Tg(Prnp-RTN3)2Yanr/J 006394 B6;129-Apba2tm1Sud Apba3tm1Sud Apba1tm1Sud/J 008364 B6;129-Chattm1(cre/ERT)Nat/J 008476 B6;129-Ncstntm1Sud/J 004807 B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/Mmjax 007605 B6;129P-Psen1tm1Vln/J 005618 B6;129P2-Bace2tm1Bdes/J 008333 B6;129P2-Dldtm1Ptl/J 002596 B6;129P2-Nos2tm1Lau/J 003822 B6;129S-Psen1tm1Shn/J 012639 B6;129S4-Mapttm3(HDAC2)Jae/J 012869 B6;129S6-Apbb2tm1Her/J 006410 B6;129S6-Chattm1(cre)Lowl/J 005993 B6;129S6-Pcsk9tm1Jdh/J 008636 B6;C-Tg(Prnp-APP695*/EYFP)49Gsn/J 007002 B6;C3-Tg(Prnp-ITM2B/APP695*42)A12Emcg/Mmjax 000231 B6;C3Fe a/a-Csf1op/J 008850 B6;SJL-Tg(Mt1-LDLR)93-4Reh/AgnJ 003378 B6C3-Tg(APP695)3Dbo Tg(PSEN1)5Dbo/J 004462 B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax 003741 B6D2-Tg(Prnp-MAPT)43Vle/J 016556 B6N.129-Ptpn5tm1Pjlo/J 006554 B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax 012621 C.129S(B6)-Chrna3tm1.1Hwrt/J 002328 C.129S2-Plautm1Mlg/J 003375 C3B6-Tg(APP695)3Dbo/Mmjax 005087 C57BL/6-Tg(Camk2a-IDE)1Selk/J 005086 C57BL/6-Tg(Camk2a-MME)3Selk/J 008833 C57BL/6-Tg(Camk2a-UBB)3413-1Fwvl/J 007027 C57BL/6-Tg(Thy1-APPSwDutIowa)BWevn/Mmjax 010800 C57BL/6-Tg(Thy1-PTGS2)300Kand/J 010703 C57BL/6-Tg(Thy1-PTGS2)303Kand/J 005706 C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J 006618 C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J 007677 CB6-Tg(Gad1-EGFP)G42Zjh/J 007072 CByJ.129P2(B6)-Nos2tm1Lau/J 006472 D2.129(B6)-Tg(APPSw)40Btla/Mmjax 007067 D2.129P2(B6)-Apoetm1Unc/J 013719 D2.Cg-Apoetm1Unc Ins2Akita/J 003718 FVB-Tg(GadGFP)45704Swn/J 013732 FVB-Tg(NPEPPS)1Skar/J 013156 FVB-Tg(tetO-CDK5R1*)1Vln/J 015815 FVB-Tg(tetO-MAPT*P301L)#Kha/J 002329 FVB.129S2-Plautm1Mlg/J 003753 FVB/N-Tg(Eno2CDK5R1)1Jdm/J 006143 FVB/N-Tg(Thy1-cre)1Vln/J 008051 NOD.129P2(B6)-Ctsbtm1Jde/RclJ 008390 STOCK Apptm1Sud/J 012640 STOCK Hdac2tm1.2Rdp/J 004808 STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J 004779 STOCK Mapttm1(EGFP)Klt/J 014092 STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J 015838 STOCK Tg(Camk2a-tTA)1Mmay Tg(tetO-ABL1*P242E*P249E)CPdav/J 014544 STOCK Tg(tetO-ABL1*P242E*P249E)CPdav/J View Alzheimer's Disease Models (108 strains)
Parkinson's Disease Models
005987 129-Achetm1Loc/J 007587 129S-Park2tm1Rpa/J 002779 129S-Parp1tm1Zqw/J 016198 129S6.Cg-Tg(Camk2a-tTA)1Mmay/JlwsJ 004608 B6(Cg)-Htra2mnd2/J 008133 B6.129-Sncbtm1Sud/J 008084 B6.129P2-Drd4tm1Dkg/J 004744 B6.129P2-Esr1tm1Ksk/J 013586 B6.129P2-Gt(ROSA)26Sortm1Nik/J 002609 B6.129P2-Nos2tm1Lau/J 008843 B6.129P2-Sncgtm1Vlb/J 016566 B6.129S-Hcn1tm2Kndl/J 004322 B6.129S1-Mapk10tm1Flv/J 003190 B6.129S2-Drd2tm1Low/J 006582 B6.129S4-Park2tm1Shn/J 005934 B6.129S4-Ucp2tm1Lowl/J 004936 B6.129S6(Cg)-Spp1tm1Blh/J 012453 B6.129X1(FVB)-Lrrk2tm1.1Cai/J 017009 B6.129X1-Nfe2l2tm1Ywk/J 009346 B6.Cg-Lrrk2tm1.1Shn/J 005491 B6.Cg-Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J 006577 B6.Cg-Park7tm1Shn/J 000567 B6.Cg-T2J +/+ Qkqk-v/J 007004 B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ 003139 B6.Cg-Tg(DBHn-lacZ)8Rpk/J 007673 B6.Cg-Tg(Gad1-EGFP)3Gfng/J 012466 B6.Cg-Tg(Lrrk2)6Yue/J 012467 B6.Cg-Tg(Lrrk2*G2019S)2Yue/J 008323 B6.Cg-Tg(Mc4r-MAPT/Sapphire)21Rck/J 008321 B6.Cg-Tg(Npy-MAPT/Sapphire)1Rck/J 008324 B6.Cg-Tg(Pmch-MAPT/CFP)1Rck/J 008322 B6.Cg-Tg(Pomc-MAPT/Topaz)1Rck/J 007894 B6.Cg-Tg(Rgs4-EGFP)4Lvt/J 012588 B6.Cg-Tg(TH-ALPP)1Erav/J 008859 B6.Cg-Tg(THY1-SNCA*A53T)F53Sud/J 008135 B6.Cg-Tg(THY1-SNCA*A53T)M53Sud/J 008601 B6.Cg-Tg(Th-cre)1Tmd/J 013583 B6.Cg-Tg(tetO-LRRK2)C7874Cai/J 000544 B6.D2-Cacna1atg/J 012445 B6.FVB-Tg(LRRK2)WT1Mjfa/J 012446 B6.FVB-Tg(LRRK2*G2019S)1Mjfa/J 006660 B6.SJL-Slc6a3tm1.1(cre)Bkmn/J 008364 B6;129-Chattm1(cre/ERT)Nat/J 009688 B6;129-Dbhtm2(Th)Rpa Thtm1Rpa/J 008883 B6;129-Gt(ROSA)26Sortm1(SNCA*A53T)Djmo/TmdJ 008889 B6;129-Gt(ROSA)26Sortm2(SNCA*119)Djmo/TmdJ 008886 B6;129-Gt(ROSA)26Sortm3(SNCA*E46K)Djmo/TmdJ 009347 B6;129-Lrrk2tm1.1Shn/J 016209 B6;129-Lrrk2tm2.1Shn/J 016210 B6;129-Lrrk2tm3.1Shn/J 013050 B6;129-Pink1tm1Aub/J 004807 B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/Mmjax 006390 B6;129-Sncatm1Sud Sncbtm1.1Sud/J 008532 B6;129-Thtm1(cre/Esr1)Nat/J 008333 B6;129P2-Dldtm1Ptl/J 008333 B6;129P2-Dldtm1Ptl/J 002596 B6;129P2-Nos2tm1Lau/J 003243 B6;129S-Tnfrsf1atm1Imx Tnfrsf1btm1Imx/J 003692 B6;129X1-Sncatm1Rosl/J 016575 B6;C3-Tg(PDGFB-LRRK2*G2019S)340Djmo/J 016576 B6;C3-Tg(PDGFB-LRRK2*R1441C)574Djmo/J 004479 B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J 000231 B6;C3Fe a/a-Csf1op/J 013725 B6;SJL-Tg(LRRK2)66Youy/J 016555 B6;SJL-Tg(Nqo1-ALPP)1Jaj/J 008473 B6;SJL-Tg(THY1-SNCA*A30P)M30Sud/J 008134 B6;SJL-Tg(THY1-SNCA*A30P)TS2Sud/J 016976 B6C3-Tg(tetO-SNCA*A53T)33Vle/J 000506 B6C3Fe a/a-Qkqk-v/J 003741 B6D2-Tg(Prnp-MAPT)43Vle/J 012621 C.129S(B6)-Chrna3tm1.1Hwrt/J 008389 C57BL/6-Tg(THY1-SNCA)1Sud/J 012769 C57BL/6-Tg(Thy1-Sncg)HvP36Putt/J 005706 C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J 006618 C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J 008245 C57BL/6J-Tg(Th-SNCA)5Eric/J 008239 C57BL/6J-Tg(Th-SNCA*A30P*A53T)39Eric/J 012441 C57BL/6J-Tg(tetO-LRRK2*G2019S)E3Cai/J 012450 C57BL/6J-Tg(tetO-SNCA)1Cai/J 016120 C57BL/6N-Lrrk1tm1.1Youy/J 016121 C57BL/6N-Lrrk2tm1.1Youy/J 016936 C57BL/6N-Tg(Thy1-SNCA)12Youy/J 017682 C57BL/6N-Tg(Thy1-SNCA)15Youy/J 007677 CB6-Tg(Gad1-EGFP)G42Zjh/J 009610 FVB/N-Tg(LRRK2)1Cjli/J 009609 FVB/N-Tg(LRRK2*G2019S)1Cjli/J 009604 FVB/N-Tg(LRRK2*R1441G)135Cjli/J 009090 FVB/NJ-Tg(Slc6a3-PARK2*Q311X)AXwy/J 010710 FVB;129S6-Sncatm1Nbm Tg(SNCA)1Nbm/J 010788 FVB;129S6-Sncatm1Nbm Tg(SNCA*A30P)1Nbm Tg(SNCA*A30P)2Nbm/J 010799 FVB;129S6-Sncatm1Nbm Tg(SNCA*A53T)1Nbm Tg(SNCA*A53T)2Nbm/J 004808 STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J 000942 STOCK Pitx3ak/2J 014092 STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J 006340 STOCK Tg(Gad1-EGFP)98Agmo/J 008474 STOCK Tg(THY1-SNCA*A53T)F53Sud/J 008132 STOCK Tg(THY1-Snca)M1mSud/J 012442 STOCK Tg(tetO-SNCA*A53T)E2Cai/J 012449 STOCK Tg(teto-LRRK2)C7874Cai/J View Parkinson's Disease Models (99 strains)
Strains carrying other alleles of MAPT
005491 B6.Cg-Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J 008323 B6.Cg-Tg(Mc4r-MAPT/Sapphire)21Rck/J 008321 B6.Cg-Tg(Npy-MAPT/Sapphire)1Rck/J 008324 B6.Cg-Tg(Pmch-MAPT/CFP)1Rck/J 008322 B6.Cg-Tg(Pomc-MAPT/Topaz)1Rck/J 004807 B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/Mmjax 003741 B6D2-Tg(Prnp-MAPT)43Vle/J 015815 FVB-Tg(tetO-MAPT*P301L)#Kha/J 004808 STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J 014092 STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J View Strains carrying other alleles of MAPT (10 strains)
Strains carrying other alleles of Prnp
003960 129S6-Tg(Prnp-GFP/cre)1Blw/J 005866 B6.Cg-Tg(APP695)3Dbo Tg(PSEN1dE9)S9Dbo/Mmjax 006006 B6.Cg-Tg(Prnp-APP)A-2Dbo/J 008596 B6.Cg-Tg(Prnp-Abca1)EHol/J 006005 B6.Cg-Tg(Prnp-App/APPswe)E1-2Dbo/Mmjax 007180 B6.Cg-Tg(Prnp-ITM2B/APP695*40)1Emcg/J 007182 B6.Cg-Tg(Prnp-ITM2B/APP695*42)A12Emcg/J 010700 B6.Cg-Tg(Prnp-TARDBP*A315T)95Balo/J 009337 B6.FVB-Tg(Prnp-RTN3)2Yanr/J 007002 B6;C3-Tg(Prnp-ITM2B/APP695*42)A12Emcg/Mmjax 004479 B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J 003378 B6C3-Tg(APP695)3Dbo Tg(PSEN1)5Dbo/J 008075 B6CBA(FVB)-Tg(Prnp-TBP*)105Xjl/J 008083 B6CBA(FVB)-Tg(Prnp-TBP*)13Xjl/J 008216 B6CBA(FVB)-Tg(Prnp-TBP*)71-16Xjl/J 003741 B6D2-Tg(Prnp-MAPT)43Vle/J 016608 C57BL/6-Tg(Prnp-TARDBP)3cPtrc/J 017604 C57BL/6-Tg(Prnp-TARDBP*M337V)4Ptrc/J 008212 STOCK Smn1tm1Msd Tg(Prnp-SMN)92Ahmb Tg(SMN2)89Ahmb/J 016144 STOCK Tg(Prnp-TARDBP)4Jlel/J 016143 STOCK Tg(Prnp-TARDBP*A315T)23Jlel/J View Strains carrying other alleles of Prnp (21 strains)
Visit the Alzheimer's Disease Mouse Model Resource site for helpful information on Alzheimer's Disease and research resources.
Visit the Parkinson's Disease Resource site for helpful information on Parkinson's and research resources.
View Mammalian Phenotype Terms
Mammalian Phenotype Terms provided by MGI
assigned by genotype
Tg(Prnp-MAPT*P301S)PS19Vle/0
involves: C3H * C57BL/6
- mortality/aging
- premature death
- ~80% of mice die by 12 months of age, with median survival of ~9 months (MGI Ref ID J:119741)
- behavior/neurological phenotype
- abnormal eating behavior
- mice are no longer able to feed after onset of paralysis (MGI Ref ID J:119741)
- hunched posture
- paralysis is associated with hunched-back posture (MGI Ref ID J:119741)
- limb grasping
- at 3 months of age, mice exhibit limb grasping and limb retraction when lifted by the tail, whereas mice expressing a wild-type MAPT transgene show no neurodegenerative phenotype up to 24 months of age (MGI Ref ID J:119741)
- paralysis
- mice show paralysis at 7-10 months of age (MGI Ref ID J:119741)
- weakness
- limb grasping at 3 months of age is followed by limb weakness (MGI Ref ID J:119741)
- nervous system phenotype
- abnormal CNS synaptic transmission
- abnormal excitatory postsynaptic potential
- at 6 months, the maximum fEPSP is reduced relative to wild-type MAPT transgenic mice (MGI Ref ID J:119741)
- reduced long term potentiation
- LTP in CA1 region of hippocampus is significantly deteriorated, indicating attenuated postsynaptic responsiveness and compromised synaptic plasticity, but at 6 months no overt reduction in neuron number is detected (MGI Ref ID J:119741)
- abnormal brain morphology
- limb grasping at 3 months of age is followed by brain atrophy (MGI Ref ID J:119741)
- abnormal amygdala morphology
- neuron loss is observed at 12 months of age (MGI Ref ID J:119741)
- abnormal brain ventricle morphology
- by 8 months of age, ventricular dilatation is seen (MGI Ref ID J:119741)
- abnormal cerebral cortex morphology
- abnormal entorhinal cortex morphology
- neuron loss is observed at 12 months of age (MGI Ref ID J:119741)
- abnormal hippocampus morphology
- at 9 months of age, there is marked hippocampal atrophy, with ~25% and ~40% reductions in hippocampal volume at 9 and 12 months of age respectively (MGI Ref ID J:119741)
- abnormal dentate gyrus morphology
- at 3 months, mice have neurofilament light chain and tau-positive spheroids in the dentate gyrus, as well as in the cortex (MGI Ref ID J:119741)
- abnormal hippocampal mossy fiber morphology
- at 3 months but not at 6 months, neurofilament light chain-positive mossy fibers are not detected in CA3 of hippocampus at 3 months but not at 6 months, neurofilament light chain-positive mossy fibers are not detected in CA3 of hippocampus (MGI Ref ID J:119741)
- abnormal hippocampus pyramidal cell morphology
- significant reduction in number in the hippocampal CA3 region is found at 12 months of age, but no loss is detected at 6 months (MGI Ref ID J:119741)
- hippocampal neuron degeneration (MGI Ref ID J:119741)
- loss of hippocampal neurons
- up to 6 months, mice show no neuron loss, but by 8 months of age, neuron loss in the hippocampus is seen, becoming more severe in hippocampus, as well as amygdala, neocortex and entorhinal cortex by 12 months of age (MGI Ref ID J:119741)
- neurofibrillary tangles
- at 6 months of age, neurofibrillary tangles (NFT) are evident in neocortex, amygdala, hippocampus, brain stem and spinal cord but none are found in mice expressing wild-type human MAPT up to 24 months of age (MGI Ref ID J:119741)
- tau protein deposits
- with aging, brains of mice have increasing levels of insoluble tau deposits composed mainly of transgenic human tau; decrease in solubility of tau is observed between 3 and 6 months (MGI Ref ID J:119741)
- at 3 months of age, mutants and mice expressing wild-type transgenic human tau show weak perikaryal and dendritic tau staining mainly in hippocampus, amygdala, cortex, brain stem, and spinal cord; at 6 months, mutants show stronger tau-positive neuronal staining in the hippocampus, amygdala, and spinal cord but older mice expressing wild-type human tau protein show no increases up to 12 months (MGI Ref ID J:119741)
- abnormal spinal cord white matter morphology
- at 3 months, mice have neurofilament light chain and tau-positive spheroids in the spinal cord white matter (MGI Ref ID J:119741)
- astrocytosis
- microglial activation precedes astrogliosis in brain regions containing NFTs; this is found in the brain and spinal cord, especially in white matter at 3 months of age with increases seen at 6 months in white and gray matter of hippocampus, amygdala, entorhinal cortex and spinal cord (MGI Ref ID J:119741)
- gliosis is striking at 6 months in the white matter where little tau pathology exists (MGI Ref ID J:119741)
- younger mice (3-4 months) show no overt gliosis but increased microglial activation is detected in the hippocampus (MGI Ref ID J:119741)
- decreased paired-pulse facilitation
- at 6 months, mice show significantly reduce paired pulse facilitation (PPF) ratio at all stimulus intervals (MGI Ref ID J:119741)
- neurodegeneration
- mice show progressive neurodegeneration starting at 1 month of age, as determined by increasing loss of synaptophysin immunoreactivity (MGI Ref ID J:119741)
- muscle phenotype
- dystrophic muscle
- affected muscles show group atrophies with small angular fibers, indicating chronic denervation of motor neurons (MGI Ref ID J:119741)
- progressive muscle weakness
- mice show motor increasing weakness and neurogenic muscular atrophy after 3 months of age (MGI Ref ID J:119741)
Tg(Prnp-MAPT*P301S)PS19Vle/Tg(Prnp-MAPT*P301S)PS19Vle
involves: C3H * C57BL/6
- behavior/neurological phenotype
- abnormal sexual interaction
- homozygous females do not mate, so mice have to be maintained as hemizygotes (MGI Ref ID J:119741)
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:
MAPT relatedNeurobiology Research
Alzheimer's Disease
Neurodegeneration
Tg(Prnp-MAPT*P301S)PS19Vle relatedNeurobiology Research
Alzheimer's Disease
Parkinson's Disease
Neurobiology Research
Alzheimer's Disease
Tau (Mapt) mutants
| Allele Symbol | Tg(Prnp-MAPT*P301S)PS19Vle | ||
|---|---|---|---|
| Allele Name | transgene insertion PS19, Virginia M Y Lee | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | P301S tau (line PS19); PS19 Tg; | ||
| Mutation Made By | Virginia Lee, University of Pennsylvania | ||
| Strain of Origin | (C57BL/6 x C3H)F1 | ||
| Expressed Gene | MAPT, microtubule-associated protein tau, human | ||
| Promoter | Prnp, prion protein, mouse, laboratory | ||
| Molecular Note | The transgene construct contains the P301S mutant human microtubule-associated protein tau, MAPT, under the direction of the mouse prion protein, Prnp, promoter. The expression of the mutant human MAPT is 5-fold higher than the expression of the endogenous mouse Mapt protein. [MGI Ref ID J:119741] | ||
Genotyping Protocols
Tg(Prnp-MAPT*P301S)PS19Vle, Standard PCR
Helpful Links
Genotyping resources and troubleshooting
Yoshiyama Y; Higuchi M; Zhang B; Huang SM; Iwata N; Saido TC; Maeda J; Suhara T; Trojanowski JQ; Lee VM. 2007. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53(3):337-51. [PubMed: 17270732] [MGI Ref ID J:119741]
Tg(Prnp-MAPT*P301S)PS19Vle relatedCarroll JC; Iba M; Bangasser DA; Valentino RJ; James MJ; Brunden KR; Lee VM; Trojanowski JQ. 2011. Chronic Stress Exacerbates Tau Pathology, Neurodegeneration, and Cognitive Performance through a Corticotropin-Releasing Factor Receptor-Dependent Mechanism in a Transgenic Mouse Model of Tauopathy. J Neurosci 31(40):14436-49. [PubMed: 21976528] [MGI Ref ID J:177434]
Dumont M; Stack C; Elipenahli C; Jainuddin S; Gerges M; Starkova NN; Yang L; Starkov AA; Beal F. 2011. Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice. FASEB J 25(11):4063-72. [PubMed: 21825035] [MGI Ref ID J:178410]
Hurtado DE; Molina-Porcel L; Iba M; Aboagye AK; Paul SM; Trojanowski JQ; Lee VM. 2010. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am J Pathol 177(4):1977-88. [PubMed: 20802182] [MGI Ref ID J:165441]
Ji B; Maeda J; Sawada M; Ono M; Okauchi T; Inaji M; Zhang MR; Suzuki K; Ando K; Staufenbiel M; Trojanowski JQ; Lee VM; Higuchi M; Suhara T. 2008. Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies. J Neurosci 28(47):12255-67. [PubMed: 19020019] [MGI Ref ID J:142367]
Maeda J; Zhang MR; Okauchi T; Ji B; Ono M; Hattori S; Kumata K; Iwata N; Saido TC; Trojanowski JQ; Lee VM; Staufenbiel M; Tomiyama T; Mori H; Fukumura T; Suhara T; Higuchi M. 2011. In Vivo Positron Emission Tomographic Imaging of Glial Responses to Amyloid-{beta} and Tau Pathologies in Mouse Models of Alzheimer's Disease and Related Disorders. J Neurosci 31(12):4720-4730. [PubMed: 21430171] [MGI Ref ID J:170310]
Min SW; Cho SH; Zhou Y; Schroeder S; Haroutunian V; Seeley WW; Huang EJ; Shen Y; Masliah E; Mukherjee C; Meyers D; Cole PA; Ott M; Gan L. 2010. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67(6):953-66. [PubMed: 20869593] [MGI Ref ID J:167861]
Takeuchi H; Iba M; Inoue H; Higuchi M; Takao K; Tsukita K; Karatsu Y; Iwamoto Y; Miyakawa T; Suhara T; Trojanowski JQ; Lee VM; Takahashi R. 2011. P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating. PLoS One 6(6):e21050. [PubMed: 21698260] [MGI Ref ID J:174441]
Yata K; Oikawa S; Sasaki R; Shindo A; Yang R; Murata M; Kanamaru K; Tomimoto H. 2011. Astrocytic neuroprotection through induction of cytoprotective molecules; a proteomic analysis of mutant P301S tau-transgenic mouse. Brain Res 1410:12-23. [PubMed: 21803337] [MGI Ref ID J:175758]
Yoshiyama Y; Kojima A; Itoh K; Uchiyama T; Arai K. 2012. Anticholinergics boost the pathological process of neurodegeneration with increased inflammation in a tauopathy mouse model. Neurobiol Dis 45(1):329-36. [PubMed: 21889983] [MGI Ref ID J:179843]
Animal Health Reports
Room Number AX11
Colony Maintenance
Breeding & Husbandry When maintaining a live colony, these mice can be bred as hemizygotes. These mice cannot be bred to homozygosity, homozygous females do not mate. Mating System Noncarrier x Hemizygote (Female x Male) 11-JUL-08 Diet Information LabDiet® 5K52/5K67
| Pricing for USA, Canada and Mexico shipping destinations |
|
![]() |
Price (US dollars $) Gender Genotypes Provided Individual Mouse $261.00 Female or Male Hemizygous for Tg(Prnp-MAPT*P301S)PS19Vle
Pairs /Price (US dollars $) Pair Genotype $321.00 Hemizygous for Tg(Prnp-MAPT*P301S)PS19Vle x Noncarrier $321.00 Noncarrier x Hemizygous for Tg(Prnp-MAPT*P301S)PS19Vle Standard Supply
Repository-Live. The Repository Strains represent an exclusive set of over 1500 unique mouse models maintained at The Jackson Laboratory to support a vast array of research areas. The breeding colonies for Repository Strains provide mice for both large and small orders and fluctuate in size depending on current demand for each strain. We treat orders for these strains as custom orders. Within 2 business days, we respond to each availability inquiry or order with various delivery options. Repository Strains typically are delivered at 4 to 8 weeks of age and will not exceed 12 weeks of age on the day of shipping.
| Pricing for International shipping destinations |
|
![]() |
Price (US dollars $) Gender Genotypes Provided Individual Mouse $339.30 Female or Male Hemizygous for Tg(Prnp-MAPT*P301S)PS19Vle
Pairs /Price (US dollars $) Pair Genotype $417.30 Hemizygous for Tg(Prnp-MAPT*P301S)PS19Vle x Noncarrier $417.30 Noncarrier x Hemizygous for Tg(Prnp-MAPT*P301S)PS19Vle Standard Supply
Repository-Live. The Repository Strains represent an exclusive set of over 1500 unique mouse models maintained at The Jackson Laboratory to support a vast array of research areas. The breeding colonies for Repository Strains provide mice for both large and small orders and fluctuate in size depending on current demand for each strain. We treat orders for these strains as custom orders. Within 2 business days, we respond to each availability inquiry or order with various delivery options. Repository Strains typically are delivered at 4 to 8 weeks of age and will not exceed 12 weeks of age on the day of shipping.
|
|
Repository-Live. The Repository Strains represent an exclusive set of over 1500 unique mouse models maintained at The Jackson Laboratory to support a vast array of research areas. The breeding colonies for Repository Strains provide mice for both large and small orders and fluctuate in size depending on current demand for each strain. We treat orders for these strains as custom orders. Within 2 business days, we respond to each availability inquiry or order with various delivery options. Repository Strains typically are delivered at 4 to 8 weeks of age and will not exceed 12 weeks of age on the day of shipping.
| Control | ||
|---|---|---|
| Noncarrier | ||
| 100010 B6C3F1/J | ||
| Considerations for Choosing Controls | ||
| Control Pricing Information for Genetically Engineered Mutant Strains. | ||
For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.